Pivekimab sunirine

DB17337ApprovedInvestigationalProtein Based Therapies

Pivekimab sunirine is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Mechanism
Curator reviewed
Primary indication
Pivekimab sunirine is indicated for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).Curator reviewed · 1 structured indication
First approval
United States, 2026
Also known as
HUMANISED IgG1 KAPPA ANTI-CD123 MONOCLONAL ANTIBODY G4723AB - SULFONATED DGN549-C CONJUGATE IMGN632
Code names
IMGN-632
Brand names
  • Decnupaz

Resolves to

Compound
UNIIL15LO3W1XXCAS2417174-95-7
Clinical / RWD
RxNorm2744296
Targets
P26951IL3RA

What you can answer from here — as of June 25, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Pivekimab sunirine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In